health.economictimes.indiatimes5d
Patents and high price barriers: Patients with rare diseases face woes to access medicines from MNCs
Patients with rare diseases in India, like Saifullah Khalidi with spinal muscular atrophy (SMA), struggle to afford ...
Rare diseases patient representatives seek govt intervention to access treatment
Patient advocates push for generic drug production to treat rare diseases, facing patent barriers and high costs.
CC Chemokine Receptor Type 5 Market Research Report 2024
The "CC Chemokine Receptor Type 5 Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The CC ...
Le Lézard6d
Abry Partners and BHMS Announce Sale of Innovisk to Ryan Specialty
Abry Partners, a Boston-based private equity firm, and BHMS Investments, LP, a Connecticut-based private equity firm, have completed the sale of Innovisk to Ryan Specialty , a leading international ...
Stop abuse of patent monopolies in rare diseases, say patient representatives and treatment activists
with no options for the drug becoming available to patients in India in sight. The drug for CF (CFTR modulators), while under monopoly, continues to be unavailable in the country due to a lack of ...
Vertex Pharmaceuticals price target raised to $408 from $361 at Canaccord
Canaccord raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $408 from $361 and keeps a Sell rating on the shares. The ...
Benzinga.com6d
Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity
Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals VRTX. And retail traders should ...
Vertex Pharmaceuticals Reports Strong Q3 2024 Growth
Vertex Pharmaceuticals Inc. ( (VRTX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex Pharmaceuticals Inc.
Mint6d
Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength
Nov 4 (Reuters) - Vertex Pharmaceuticals raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments. The drugmaker now ...
Reuters6d
Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength
Nov 4 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF ...